{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+I+Arm+B", "query": { "intervention": "Phase I Arm B" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 850, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+I+Arm+B&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T15:54:57.713Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01117623", "title": "Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg", "type": "DRUG" }, { "name": "HCC Child-Pugh A expansion cohort: Regorafenib 100 mg", "type": "DRUG" }, { "name": "HCC Child-Pugh B expansion cohort: Regorafenib 100 mg", "type": "DRUG" }, { "name": "NSCLC expansion cohort: Regorafenib 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2007-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117623" }, { "nct_id": "NCT06316297", "title": "Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acne" ], "interventions": [ { "name": "Acne mRNA vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 800, "start_date": "2024-04-05", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 79, "location_summary": "Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Lafayette", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06316297" }, { "nct_id": "NCT03743246", "title": "A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "JCAR017", "type": "DRUG" }, { "name": "Lymphodepleting", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 21, "start_date": "2018-10-17", "completion_date": "2024-01-26", "has_results": true, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 9, "location_summary": "Duarte, California • Redwood City, California • St. Petersburg, Florida + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03743246" }, { "nct_id": "NCT03425461", "title": "Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Anti-SEMA4D Monoclonal Antibody VX15/2503", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-06-14", "completion_date": "2021-03-04", "has_results": false, "last_update_posted_date": "2021-04-02", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 2, "location_summary": "Los Angeles, California • Salt Lake City, Utah", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03425461" }, { "nct_id": "NCT01189240", "title": "RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2010-12", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2015-12-14", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189240" }, { "nct_id": "NCT02166463", "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ann Arbor Stage IIB Hodgkin Lymphoma", "Ann Arbor Stage IIIB Hodgkin Lymphoma", "Ann Arbor Stage IVA Hodgkin Lymphoma", "Ann Arbor Stage IVB Hodgkin Lymphoma", "Childhood Hodgkin Lymphoma", "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Bleomycin Sulfate", "type": "BIOLOGICAL" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "2 Years to 22 Years" }, "enrollment_count": 600, "start_date": "2015-03-19", "completion_date": "2026-10-03", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 182, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02166463" }, { "nct_id": "NCT04151563", "title": "A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-small Cell Lung Cancer" ], "interventions": [ { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "cabozantinib", "type": "DRUG" }, { "name": "docetaxel", "type": "BIOLOGICAL" }, { "name": "ramucirumab", "type": "BIOLOGICAL" }, { "name": "lucitanib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-04-15", "completion_date": "2026-05-13", "has_results": false, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04151563" }, { "nct_id": "NCT04776317", "title": "Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "ChAdV68-S", "type": "BIOLOGICAL" }, { "name": "ChAdV68-S-TCE", "type": "BIOLOGICAL" }, { "name": "SAM-LNP-S", "type": "BIOLOGICAL" }, { "name": "SAM-LNP-S-TCE", "type": "BIOLOGICAL" }, { "name": "Sodium Chloride, 0.9%", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 81, "start_date": "2021-03-25", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 4, "location_summary": "Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04776317" }, { "nct_id": "NCT06159621", "title": "CD40 Agonist and PD-1 Inhibitor in HNSCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "PD-1inhibitor - LVGN 3616", "type": "DRUG" }, { "name": "CD 40 Agonist - LVGN 7409", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-07-02", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06159621" }, { "nct_id": "NCT03298516", "title": "A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "DCLL9718S", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2017-11-15", "completion_date": "2019-07-16", "has_results": false, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-09-02T15:54:57.713Z", "location_count": 5, "location_summary": "Duarte, California • Aurora, Colorado • New Haven, Connecticut + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298516" } ] }